Trial Profile
A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 14 Mar 2012 Additional lead trial centre (National Institutes of Health Clinical Center) identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial centre (National Institutes of Health Clinical Center) identified as reported by ClinicalTrials.gov.
- 11 Jan 2009 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.